Comparing the current results to its competitors, Grail Inc reported Revenue increase in the 1 quarter 2026 by 28.11 % year on year. The sales growth was above Grail Inc 's competitors' average revenue growth of 9.28 %, achieved in the same quarter.
Grail Inc 's Comment on Competition and Industry Peers
The company identifies its key competitors in the cancer detection and precision oncology market as Roche/Foundation Medicine, Inc., Natera, Inc., Guardant, Inc., Tempus AI, Inc., Clearnote Health, NeoGenomics Laboratories, Personalis, Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp. It emphasizes its competitive position based on a substantial intellectual property portfolio, extensive research, multidisciplinary capabilities utilizing next-generation sequencing (NGS), large clinical studies, advanced machine learning techniques, and significant investments in facilities and operational workflows. The company focuses on blood-based technologies aimed at improving cancer care through therapy selection, monitoring, and relapse detection.
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.
Fortrea Holdings Inc is a company that operates through its subsidiaries in the business of software and technology services, providing innovative solutions and products to its clients. Its business model focuses on developing and delivering custom software applications, digital platforms, and consulting services to cater to the specific needs of various industries.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Sources:
Grail Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Grail Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
